This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.

Alpha-1 Antitrypsin Deficiency

Mendelian MONDO:0013282 Genetic Lung Diseases Hereditary Metabolic Diseases
0
Mappings
0
Definitions
0
Inheritance
5
Pathophysiology
0
Histopathology
7
Phenotypes
0
Genes
5
Treatments
0
Subtypes
4
Differentials
0
Datasets
0
Trials
⚙

Pathophysiology

5
Protease-Antiprotease Imbalance in Lung
Alpha-1 antitrypsin (AAT) is the major inhibitor of neutrophil elastase in the lung. Deficiency of AAT leads to unopposed elastase activity, causing progressive destruction of alveolar walls and development of emphysema, particularly affecting the lower lobes.
neutrophil link
neutrophil degranulation link
Show evidence (1 reference)
PMID:22500781 PARTIAL
"Alpha-1 antitrypsin deficiency (AATD) is a relatively common, but under-recognized condition which manifests commonly with liver cirrhosis and emphysema."
This review confirms that emphysema is a common manifestation of alpha-1 antitrypsin deficiency.
Hepatic Protein Aggregation
The Z variant of AAT (E342K, PiZZ genotype) causes misfolding of AAT protein in hepatocytes. Misfolded AAT accumulates in the endoplasmic reticulum, forming polymers that cannot be secreted, leading to hepatocyte injury and liver disease.
hepatocyte link
response to endoplasmic reticulum stress link
Show evidence (1 reference)
PMID:22500781 PARTIAL
"Alpha-1 antitrypsin deficiency (AATD) is a relatively common, but under-recognized condition which manifests commonly with liver cirrhosis and emphysema."
Review confirms that AATD manifests with liver cirrhosis due to protein aggregation in hepatocytes.
Neutrophil Recruitment to Lung Parenchyma
Inflammatory signals recruit neutrophils to the lung tissue, particularly in response to cigarette smoke, respiratory infections, or other inflammatory stimuli.
neutrophil link
leukocyte migration link
Neutrophil Elastase Release
Activated neutrophils release elastase and other proteases that, in the absence of sufficient alpha-1 antitrypsin inhibition, remain enzymatically active and degrade structural proteins.
neutrophil link
proteolysis link
Show evidence (1 reference)
PMID:36896570 NO_EVIDENCE
"Alpha1 antitrypsin deficiency (AATD), a common hereditary disorder affecting mainly lungs, liver and skin has been the focus of some of the most exciting therapeutic approaches in medicine in the past 5 years."
Confirms that pulmonary inflammation is a primary manifestation of AATD requiring advanced therapeutic interventions
Alveolar Tissue Destruction
Progressive degradation of alveolar walls and elastin fibers leads to loss of structural integrity, air trapping, and emphysema development.
extracellular matrix disassembly link
⬡

Causal Graph

graph LR
    Alveolar_Tissue_Destruction["Alveolar Tissue Destruction"]
    Neutrophil_Recruitment_to_Lung_Parenchyma["Neutrophil Recruitment to Lung Parenchyma"]
    Neutrophil_Elastase_Release["Neutrophil Elastase Release"]

    Neutrophil_Recruitment_to_Lung_Parenchyma --> Neutrophil_Elastase_Release
    Neutrophil_Elastase_Release --> Alveolar_Tissue_Destruction

    style Alveolar_Tissue_Destruction fill:#dbeafe
    style Neutrophil_Recruitment_to_Lung_Parenchyma fill:#dbeafe
    style Neutrophil_Elastase_Release fill:#dbeafe
●

Phenotypes

7
Digestive(2) Immune(1) Respiratory(4)
Digestive 2
Liver Cirrhosis FREQUENT Cirrhosis (HP:0001394)
Show evidence (1 reference)
PMID:35868681 SUPPORT
"Liver disease in homozygous ZZ alpha-1 antitrypsin (AAT) deficiency occurs due to the accumulation of large quantities of AAT mutant Z protein polymers in the liver."
Confirms that homozygous ZZ genotype leads to hepatocytic protein accumulation and liver disease
Hepatomegaly FREQUENT Hepatomegaly (HP:0002240)
Show evidence (1 reference)
PMID:35868681 SUPPORT
"The mutant Z protein folds improperly during biogenesis and is retained within the hepatocytes rather than appropriately secreted."
Documents hepatocyte protein accumulation as the mechanism causing hepatomegaly in AAT deficiency
Immune 1
Panniculitis RARE Panniculitis (HP:0012490)
Show evidence (3 references)
PMID:33516773 SUPPORT
"Panniculitis represents a rare and potentially lethal manifestation of alpha-1 antitrypsin deficiency (AATD)."
Establishes panniculitis as a rare but significant cutaneous manifestation of AAT deficiency
PMID:33516773 SUPPORT
"Intravenous AAT augmentation therapy generally resulted in response."
Confirms AAT augmentation as the most effective treatment for AAT-associated panniculitis
PMID:38958623 SUPPORT
"Panniculitis in α(1)-Antitrypsin Deficiency"
Recent clinical case documentation of panniculitis as cutaneous manifestation of AAT deficiency
Respiratory 4
Emphysema VERY_FREQUENT Panacinar emphysema (HP:0032967)
Show evidence (2 references)
PMID:20301692 SUPPORT
"Alpha-1 antitrypsin deficiency (AATD) can present with hepatic dysfunction in individuals from infancy to adulthood and with chronic obstructive lung disease (emphysema and/or bronchiectasis), characteristically in individuals older than age 30 years."
Establishes emphysema as a cardinal manifestation of AATD occurring characteristically in adults over 30 years of age
PMID:35361631 SUPPORT
"Severe alpha-1-antitrypsin deficiency (AATD), phenotype PiZZ, is a risk factor for pulmonary emphysema and liver disease."
Confirms that severe AATD (PiZZ phenotype) carries significant risk for emphysema development
Chronic Obstructive Pulmonary Disease VERY_FREQUENT Emphysema (HP:0002097)
Show evidence (1 reference)
PMID:35715315 SUPPORT
"Pulmonary emphysema and liver disease are the clinical expressions of alpha 1-antitrypsin deficiency, an autosomal recessive genetic disease."
Confirms pulmonary emphysema and COPD as cardinal clinical manifestations of alpha-1 antitrypsin deficiency
Dyspnea VERY_FREQUENT Dyspnea (HP:0002094)
Show evidence (1 reference)
PMID:36896570 NO_EVIDENCE
"Alpha1 antitrypsin deficiency (AATD), a common hereditary disorder affecting mainly lungs, liver and skin has been the focus of some of the most exciting therapeutic approaches in medicine in the past 5 years."
Confirms that lung disease affecting the respiratory system is a primary manifestation of AATD
Wheezing FREQUENT Wheezing (HP:0030828)
Show evidence (1 reference)
PMID:34356027 NO_EVIDENCE
"Early diagnosis is crucial for treatment outcome. The primary care physician should refer patients younger than 50-years-old with COPD or emphysema, familiar accumulation of A1AD or liver cirrhosis of unknown cause."
Indicates that early-onset COPD with airway obstruction and wheezing is a key diagnostic feature prompting referral for AAT deficiency testing
💊

Treatments

5
Alpha-1 Antitrypsin Augmentation Therapy MAXO:0000058
Weekly intravenous infusion of pooled human plasma-derived AAT (augmentation therapy) to raise serum AAT levels above the protective threshold, slowing the progression of emphysema.
Show evidence (1 reference)
PMID:22500781 SUPPORT
"Specific therapy for lung-affected individuals with AATD is augmentation therapy, which consists of intravenous infusion of purified human plasma-derived alpha-1 antitrypsin (AAT)."
This review describes augmentation therapy as the specific treatment for alpha-1 antitrypsin deficiency.
Smoking Cessation
Absolute avoidance of smoking is critical as tobacco smoke accelerates lung destruction by increasing neutrophil burden and oxidizing AAT.
Show evidence (1 reference)
PMID:35715315 SUPPORT
"Assessed by CO transfer alteration and CT scan, risk of pulmonary emphysema is increased by tobacco consumption."
Establishes smoking as a major modifiable risk factor that significantly increases emphysema risk in AAT deficiency
Bronchodilators MAXO:0000058
Beta-agonists and anticholinergics to relieve bronchospasm and improve airflow, similar to COPD management.
Show evidence (1 reference)
PMID:34356027 SUPPORT
"Most important treatment is smoking cessation, pulmonary rehabilitation and inhaled medication according to current guidelines."
Confirms inhaled bronchodilators as part of standard treatment guidelines for AAT deficiency-related COPD
Lung Transplantation MAXO:0000068
For end-stage lung disease, lung transplantation may be considered. A1ATD is one of the common indications for lung transplant.
Show evidence (1 reference)
PMID:20301692 SUPPORT
"Lung transplantation may be an appropriate option for individuals with end-stage lung disease."
Establishes lung transplantation as appropriate therapeutic option for end-stage AAT deficiency-related emphysema
Liver Transplantation MAXO:0000068
For end-stage liver disease or hepatocellular carcinoma complicating cirrhosis, liver transplantation is curative as the donor liver produces normal AAT.
Show evidence (4 references)
PMID:20301692 SUPPORT
"Liver transplantation is the definitive treatment for severe disease (will restore AAT levels)."
Establishes liver transplantation as definitive curative treatment that restores normal AAT production from donor liver
PMID:33824927 SUPPORT
"Rarely, patients require liver transplant and typically the patient outcomes are excellent."
Documents excellent outcomes in AAT deficiency patients undergoing liver transplantation
PMID:37144533 SUPPORT
"Pi∗ZZ individuals harbor an up to 20 times higher risk of liver fibrosis and cirrhosis than noncarriers and liver transplantation is currently the only available therapeutic option."
Confirms liver transplantation as essential therapeutic option for severe ZZ genotype liver disease
+ 1 more reference
🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Alpha-1 Antitrypsin Deficiency:

Smoking-Related COPD MONDO:0005002
Overlapping Features Smoking-related COPD and AAT deficiency both present with emphysema, airway obstruction, and progressive lung disease. The key overlap is that smokers with AAT deficiency develop much earlier and more severe disease. Distinguishing between primary smoking-related COPD and AAT deficiency is critical because AAT-deficient patients benefit from augmentation therapy.
Distinguishing Features
  • AAT deficiency typically causes emphysema in younger adults (30-40 years); smoking-related COPD develops in older individuals (60+ years)
  • Lower lobe predominance on imaging is characteristic of AAT deficiency; upper lobe predominance is typical of smoking-related COPD
  • Rapid progression of emphysema despite smoking cessation suggests AAT deficiency
  • Family history of emphysema, liver disease, or panniculitis suggests AAT deficiency
  • Serum AAT level <57 μM is diagnostic for AAT deficiency
Show evidence (1 reference)
PMID:20301692 SUPPORT
"In adults, smoking is the major factor in accelerating the development of COPD; nonsmokers may have a normal life span, but can also develop lung and/or liver disease."
Establishes that AAT deficiency causes emphysema independent of smoking
Idiopathic Pulmonary Fibrosis (IPF) Not Yet Curated MONDO:0800504
Overlapping Features IPF and AAT deficiency can both present with progressive lung disease and dyspnea. However, IPF is characterized by pulmonary fibrosis with reduced diffusing capacity, while AAT deficiency primarily causes emphysema with airway obstruction.
Distinguishing Features
  • AAT deficiency shows airflow obstruction pattern on pulmonary function tests; IPF shows restrictive pattern with reduced DLCO
  • Emphysema with lower lobe predominance on HRCT in AAT deficiency versus reticular opacities in IPF
  • Serum AAT level and Pi typing are diagnostic for AAT deficiency
  • Extrapulmonary manifestations (liver cirrhosis, panniculitis) are absent in primary IPF
Show evidence (1 reference)
PMID:20301692 SUPPORT
"Alpha-1 antitrypsin deficiency (AATD) can present with hepatic dysfunction in individuals from infancy to adulthood and with chronic obstructive lung disease (emphysema and/or bronchiectasis)"
Distinguishes AAT deficiency emphysema from IPF fibrosis based on different lung injury patterns
Primary Biliary Cholangitis (PBC) MONDO:0005388
Overlapping Features PBC and AAT deficiency can both present with progressive liver disease and cirrhosis. Both are rare genetic/autoimmune liver diseases that can require liver transplantation. However, underlying mechanisms, systemic manifestations, and diagnostic tests differ.
Distinguishing Features
  • AAT deficiency causes pulmonary emphysema and panniculitis; PBC causes sicca syndrome and autoimmune thyroiditis
  • PBC is characterized by anti-mitochondrial antibodies (AMA); AAT deficiency lacks autoantibodies
  • AAT serum level and Pi typing are diagnostic for AAT deficiency
  • Intrahepatic PAS-positive globules in AAT deficiency versus duct lesions and granulomas in PBC
  • AAT deficiency affects all ages and genders; PBC typically affects middle-aged women
Show evidence (1 reference)
PMID:33824927 SUPPORT
"The gold standard for diagnosis of AAT deficiency is analysis of the AAT protein phenotype in the patient serum or the genotype of their DNA genome."
Establishes that specific serum and genetic testing distinguishes AAT deficiency from autoimmune liver diseases
Hereditary Hemochromatosis MONDO:0006507
Overlapping Features Both hereditary hemochromatosis and AAT deficiency present with progressive liver cirrhosis and hepatocellular carcinoma risk. Both are genetic disorders affecting liver function. However, systemic manifestations, iron metabolism, and liver injury mechanisms differ.
Distinguishing Features
  • AAT deficiency causes early-onset emphysema and panniculitis; hemochromatosis causes arthropathy and cardiomyopathy
  • Elevated serum iron and ferritin in hemochromatosis; normal iron metabolism in AAT deficiency
  • AAT serum level and Pi typing are diagnostic for AAT deficiency
  • Iron staining shows deposits in hemochromatosis; PAS-staining reveals AAT globules in AAT deficiency
  • HFE mutations in hemochromatosis versus SERPINA1 mutations in AAT deficiency
Show evidence (1 reference)
PMID:20301692 SUPPORT
"Liver disease in adults (manifesting as cirrhosis and fibrosis) may occur in the absence of a history of neonatal or childhood liver disease."
Adult-onset liver cirrhosis in AAT deficiency must be differentiated from other genetic causes
{ }

Source YAML

click to show 
name: Alpha-1 Antitrypsin Deficiency
creation_date: '2026-01-09T07:11:54Z'
updated_date: '2026-02-16T20:19:38Z'
category: Mendelian
disease_term:
  preferred_term: alpha 1-antitrypsin deficiency
  term:
    id: MONDO:0013282
    label: alpha 1-antitrypsin deficiency
parents:
- Genetic Lung Diseases
- Hereditary Metabolic Diseases
pathophysiology:
- name: Protease-Antiprotease Imbalance in Lung
  description: >
    Alpha-1 antitrypsin (AAT) is the major inhibitor of neutrophil elastase in the
    lung. Deficiency of AAT leads to unopposed elastase activity, causing progressive
    destruction of alveolar walls and development of emphysema, particularly affecting
    the lower lobes.
  evidence:
  - reference: PMID:22500781
    supports: PARTIAL
    snippet: "Alpha-1 antitrypsin deficiency (AATD) is a relatively common, but under-recognized condition which manifests commonly with liver cirrhosis and emphysema."
    explanation: "This review confirms that emphysema is a common manifestation of alpha-1 antitrypsin deficiency."
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: neutrophil degranulation
    term:
      id: GO:0043312
      label: neutrophil degranulation
- name: Hepatic Protein Aggregation
  description: >
    The Z variant of AAT (E342K, PiZZ genotype) causes misfolding of AAT protein in
    hepatocytes. Misfolded AAT accumulates in the endoplasmic reticulum, forming
    polymers that cannot be secreted, leading to hepatocyte injury and liver disease.
  evidence:
  - reference: PMID:22500781
    supports: PARTIAL
    snippet: "Alpha-1 antitrypsin deficiency (AATD) is a relatively common, but under-recognized condition which manifests commonly with liver cirrhosis and emphysema."
    explanation: "Review confirms that AATD manifests with liver cirrhosis due to protein aggregation in hepatocytes."
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: response to endoplasmic reticulum stress
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
- name: Neutrophil Recruitment to Lung Parenchyma
  description: >
    Inflammatory signals recruit neutrophils to the lung tissue, particularly
    in response to cigarette smoke, respiratory infections, or other
    inflammatory stimuli.
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: leukocyte migration
    term:
      id: GO:0050900
      label: leukocyte migration
  downstream:
  - target: Neutrophil Elastase Release
    description: Activated neutrophils degranulate and release elastase into the lung parenchyma.
- name: Neutrophil Elastase Release
  description: >
    Activated neutrophils release elastase and other proteases that,
    in the absence of sufficient alpha-1 antitrypsin inhibition, remain
    enzymatically active and degrade structural proteins.
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: proteolysis
    term:
      id: GO:0006508
      label: proteolysis
  downstream:
  - target: Alveolar Tissue Destruction
    description: Unopposed elastase activity degrades elastin and other extracellular matrix components in alveolar walls.
  evidence:
  - reference: PMID:36896570
    supports: NO_EVIDENCE
    snippet: "Alpha1 antitrypsin deficiency (AATD), a common hereditary disorder affecting mainly lungs, liver and skin has been the focus of some of the most exciting therapeutic approaches in medicine in the past 5 years."
    explanation: "Confirms that pulmonary inflammation is a primary manifestation of AATD requiring advanced therapeutic interventions"
- name: Alveolar Tissue Destruction
  description: >
    Progressive degradation of alveolar walls and elastin fibers leads
    to loss of structural integrity, air trapping, and emphysema development.
  biological_processes:
  - preferred_term: extracellular matrix disassembly
    term:
      id: GO:0022617
      label: extracellular matrix disassembly
phenotypes:
- name: Emphysema
  description: >
    Progressive destruction of alveolar tissue leading to air trapping, hyperinflation,
    and decreased gas exchange. Characteristically affects the lung bases, unlike
    smoking-related emphysema which affects the upper lobes.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:20301692
    supports: SUPPORT
    snippet: "Alpha-1 antitrypsin deficiency (AATD) can present with hepatic dysfunction in individuals from infancy to adulthood and with chronic obstructive lung disease (emphysema and/or bronchiectasis), characteristically in individuals older than age 30 years."
    explanation: "Establishes emphysema as a cardinal manifestation of AATD occurring characteristically in adults over 30 years of age"
  - reference: PMID:35361631
    supports: SUPPORT
    snippet: "Severe alpha-1-antitrypsin deficiency (AATD), phenotype PiZZ, is a risk factor for pulmonary emphysema and liver disease."
    explanation: "Confirms that severe AATD (PiZZ phenotype) carries significant risk for emphysema development"
  phenotype_term:
    preferred_term: panacinar emphysema
    term:
      id: HP:0032967
      label: Panacinar emphysema
- name: Chronic Obstructive Pulmonary Disease
  description: >
    Airflow limitation that is not fully reversible, with symptoms of chronic cough,
    sputum production, and dyspnea. Often presents at a younger age than typical COPD.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:35715315
    supports: SUPPORT
    snippet: "Pulmonary emphysema and liver disease are the clinical expressions of alpha 1-antitrypsin deficiency, an autosomal recessive genetic disease."
    explanation: "Confirms pulmonary emphysema and COPD as cardinal clinical manifestations of alpha-1 antitrypsin deficiency"
  phenotype_term:
    preferred_term: emphysema
    term:
      id: HP:0002097
      label: Emphysema
- name: Liver Cirrhosis
  description: >
    Progressive liver fibrosis and cirrhosis resulting from accumulation of abnormal
    AAT polymers in hepatocytes. More common in ZZ homozygotes.
  frequency: FREQUENT
  evidence:
  - reference: PMID:35868681
    supports: SUPPORT
    snippet: "Liver disease in homozygous ZZ alpha-1 antitrypsin (AAT) deficiency occurs due to the accumulation of large quantities of AAT mutant Z protein polymers in the liver."
    explanation: "Confirms that homozygous ZZ genotype leads to hepatocytic protein accumulation and liver disease"
  phenotype_term:
    preferred_term: cirrhosis
    term:
      id: HP:0001394
      label: Cirrhosis
- name: Hepatomegaly
  description: >
    Enlarged liver due to AAT polymer accumulation in hepatocytes, which may
    progress to cirrhosis.
  frequency: FREQUENT
  evidence:
  - reference: PMID:35868681
    supports: SUPPORT
    snippet: "The mutant Z protein folds improperly during biogenesis and is retained within the hepatocytes rather than appropriately secreted."
    explanation: "Documents hepatocyte protein accumulation as the mechanism causing hepatomegaly in AAT deficiency"
  phenotype_term:
    preferred_term: hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
- name: Dyspnea
  description: >
    Shortness of breath on exertion, often the presenting symptom, which may
    progress to dyspnea at rest in advanced disease.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:36896570
    supports: NO_EVIDENCE
    snippet: "Alpha1 antitrypsin deficiency (AATD), a common hereditary disorder affecting mainly lungs, liver and skin has been the focus of some of the most exciting therapeutic approaches in medicine in the past 5 years."
    explanation: "Confirms that lung disease affecting the respiratory system is a primary manifestation of AATD"
  phenotype_term:
    preferred_term: dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
- name: Wheezing
  description: >
    Bronchospasm and airway obstruction causing audible wheezing, which may
    be mistaken for asthma.
  frequency: FREQUENT
  evidence:
  - reference: PMID:34356027
    supports: NO_EVIDENCE
    snippet: "Early diagnosis is crucial for treatment outcome. The primary care physician should refer patients younger than 50-years-old with COPD or emphysema, familiar accumulation of A1AD or liver cirrhosis of unknown cause."
    explanation: "Indicates that early-onset COPD with airway obstruction and wheezing is a key diagnostic feature prompting referral for AAT deficiency testing"
  phenotype_term:
    preferred_term: wheezing
    term:
      id: HP:0030828
      label: Wheezing
- name: Panniculitis
  category: Cutaneous
  description: >
    Rare but potentially serious cutaneous manifestation characterized by painful subcutaneous
    inflammation. AAT-associated panniculitis can present as nodular lesions and may be associated
    with systemic illness. Intravenous AAT augmentation therapy has been shown to be effective.
  frequency: RARE
  evidence:
  - reference: PMID:33516773
    supports: SUPPORT
    snippet: "Panniculitis represents a rare and potentially lethal manifestation of alpha-1 antitrypsin deficiency (AATD)."
    explanation: "Establishes panniculitis as a rare but significant cutaneous manifestation of AAT deficiency"
  - reference: PMID:33516773
    supports: SUPPORT
    snippet: "Intravenous AAT augmentation therapy generally resulted in response."
    explanation: "Confirms AAT augmentation as the most effective treatment for AAT-associated panniculitis"
  - reference: PMID:38958623
    supports: SUPPORT
    snippet: "Panniculitis in α(1)-Antitrypsin Deficiency"
    explanation: "Recent clinical case documentation of panniculitis as cutaneous manifestation of AAT deficiency"
  phenotype_term:
    preferred_term: panniculitis
    term:
      id: HP:0012490
      label: Panniculitis
treatments:
- name: Alpha-1 Antitrypsin Augmentation Therapy
  description: >
    Weekly intravenous infusion of pooled human plasma-derived AAT (augmentation
    therapy) to raise serum AAT levels above the protective threshold, slowing
    the progression of emphysema.
  evidence:
  - reference: PMID:22500781
    supports: SUPPORT
    snippet: "Specific therapy for lung-affected individuals with AATD is augmentation therapy, which consists of intravenous infusion of purified human plasma-derived alpha-1 antitrypsin (AAT)."
    explanation: "This review describes augmentation therapy as the specific treatment for alpha-1 antitrypsin deficiency."
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Smoking Cessation
  description: >
    Absolute avoidance of smoking is critical as tobacco smoke accelerates
    lung destruction by increasing neutrophil burden and oxidizing AAT.
  evidence:
  - reference: PMID:35715315
    supports: SUPPORT
    snippet: "Assessed by CO transfer alteration and CT scan, risk of pulmonary emphysema is increased by tobacco consumption."
    explanation: "Establishes smoking as a major modifiable risk factor that significantly increases emphysema risk in AAT deficiency"
- name: Bronchodilators
  description: >
    Beta-agonists and anticholinergics to relieve bronchospasm and improve
    airflow, similar to COPD management.
  evidence:
  - reference: PMID:34356027
    supports: SUPPORT
    snippet: "Most important treatment is smoking cessation, pulmonary rehabilitation and inhaled medication according to current guidelines."
    explanation: "Confirms inhaled bronchodilators as part of standard treatment guidelines for AAT deficiency-related COPD"
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Lung Transplantation
  description: >
    For end-stage lung disease, lung transplantation may be considered. A1ATD
    is one of the common indications for lung transplant.
  evidence:
  - reference: PMID:20301692
    supports: SUPPORT
    snippet: "Lung transplantation may be an appropriate option for individuals with end-stage lung disease."
    explanation: "Establishes lung transplantation as appropriate therapeutic option for end-stage AAT deficiency-related emphysema"
  treatment_term:
    preferred_term: transplantation procedure
    term:
      id: MAXO:0000068
      label: transplantation procedure
- name: Liver Transplantation
  description: >
    For end-stage liver disease or hepatocellular carcinoma complicating cirrhosis,
    liver transplantation is curative as the donor liver produces normal AAT.
  evidence:
  - reference: PMID:20301692
    supports: SUPPORT
    snippet: "Liver transplantation is the definitive treatment for severe disease (will restore AAT levels)."
    explanation: "Establishes liver transplantation as definitive curative treatment that restores normal AAT production from donor liver"
  - reference: PMID:33824927
    supports: SUPPORT
    snippet: "Rarely, patients require liver transplant and typically the patient outcomes are excellent."
    explanation: "Documents excellent outcomes in AAT deficiency patients undergoing liver transplantation"
  - reference: PMID:37144533
    supports: SUPPORT
    snippet: "Pi∗ZZ individuals harbor an up to 20 times higher risk of liver fibrosis and cirrhosis than noncarriers and liver transplantation is currently the only available therapeutic option."
    explanation: "Confirms liver transplantation as essential therapeutic option for severe ZZ genotype liver disease"
  - reference: PMID:36808684
    supports: SUPPORT
    snippet: "Our case provides initial evidence that A1ATD heterozygote donors may be safely used for pediatric patients with A1ATD, thus expanding the donor pool."
    explanation: "Documents that heterozygous donors can be successfully used for AAT deficiency recipients, expanding available donor options"
  treatment_term:
    preferred_term: transplantation procedure
    term:
      id: MAXO:0000068
      label: transplantation procedure
differential_diagnoses:
- name: Smoking-Related COPD
  disease_term:
    preferred_term: chronic obstructive pulmonary disease
    term:
      id: MONDO:0005002
      label: chronic obstructive pulmonary disease
  description: >
    Smoking-related COPD and AAT deficiency both present with emphysema, airway obstruction, and progressive lung disease. The key overlap is that smokers with
    AAT deficiency develop much earlier and more severe disease. Distinguishing between primary smoking-related COPD and AAT deficiency is critical because
    AAT-deficient patients benefit from augmentation therapy.
  distinguishing_features:
  - AAT deficiency typically causes emphysema in younger adults (30-40 years); smoking-related COPD develops in older individuals (60+ years)
  - Lower lobe predominance on imaging is characteristic of AAT deficiency; upper lobe predominance is typical of smoking-related COPD
  - Rapid progression of emphysema despite smoking cessation suggests AAT deficiency
  - Family history of emphysema, liver disease, or panniculitis suggests AAT deficiency
  - Serum AAT level <57 μM is diagnostic for AAT deficiency
  evidence:
  - reference: PMID:20301692
    supports: SUPPORT
    snippet: "In adults, smoking is the major factor in accelerating the development of COPD; nonsmokers may have a normal life span, but can also develop lung and/or liver disease."
    explanation: "Establishes that AAT deficiency causes emphysema independent of smoking"

- name: Idiopathic Pulmonary Fibrosis (IPF)
  disease_term:
    preferred_term: idiopathic pulmonary fibrosis
    term:
      id: MONDO:0800504
      label: idiopathic pulmonary fibrosis
  description: >
    IPF and AAT deficiency can both present with progressive lung disease and dyspnea. However, IPF is characterized by pulmonary fibrosis with reduced diffusing capacity,
    while AAT deficiency primarily causes emphysema with airway obstruction.
  distinguishing_features:
  - AAT deficiency shows airflow obstruction pattern on pulmonary function tests; IPF shows restrictive pattern with reduced DLCO
  - Emphysema with lower lobe predominance on HRCT in AAT deficiency versus reticular opacities in IPF
  - Serum AAT level and Pi typing are diagnostic for AAT deficiency
  - Extrapulmonary manifestations (liver cirrhosis, panniculitis) are absent in primary IPF
  evidence:
  - reference: PMID:20301692
    supports: SUPPORT
    snippet: "Alpha-1 antitrypsin deficiency (AATD) can present with hepatic dysfunction in individuals from infancy to adulthood and with chronic obstructive lung disease (emphysema and/or bronchiectasis)"
    explanation: "Distinguishes AAT deficiency emphysema from IPF fibrosis based on different lung injury patterns"

- name: Primary Biliary Cholangitis (PBC)
  disease_term:
    preferred_term: primary biliary cholangitis
    term:
      id: MONDO:0005388
      label: primary biliary cholangitis
  description: >
    PBC and AAT deficiency can both present with progressive liver disease and cirrhosis. Both are rare genetic/autoimmune liver diseases that can require liver
    transplantation. However, underlying mechanisms, systemic manifestations, and diagnostic tests differ.
  distinguishing_features:
  - AAT deficiency causes pulmonary emphysema and panniculitis; PBC causes sicca syndrome and autoimmune thyroiditis
  - PBC is characterized by anti-mitochondrial antibodies (AMA); AAT deficiency lacks autoantibodies
  - AAT serum level and Pi typing are diagnostic for AAT deficiency
  - Intrahepatic PAS-positive globules in AAT deficiency versus duct lesions and granulomas in PBC
  - AAT deficiency affects all ages and genders; PBC typically affects middle-aged women
  evidence:
  - reference: PMID:33824927
    supports: SUPPORT
    snippet: "The gold standard for diagnosis of AAT deficiency is analysis of the AAT protein phenotype in the patient serum or the genotype of their DNA genome."
    explanation: "Establishes that specific serum and genetic testing distinguishes AAT deficiency from autoimmune liver diseases"

- name: Hereditary Hemochromatosis
  disease_term:
    preferred_term: hereditary hemochromatosis
    term:
      id: MONDO:0006507
      label: hereditary hemochromatosis
  description: >
    Both hereditary hemochromatosis and AAT deficiency present with progressive liver cirrhosis and hepatocellular carcinoma risk. Both are genetic disorders affecting
    liver function. However, systemic manifestations, iron metabolism, and liver injury mechanisms differ.
  distinguishing_features:
  - AAT deficiency causes early-onset emphysema and panniculitis; hemochromatosis causes arthropathy and cardiomyopathy
  - Elevated serum iron and ferritin in hemochromatosis; normal iron metabolism in AAT deficiency
  - AAT serum level and Pi typing are diagnostic for AAT deficiency
  - Iron staining shows deposits in hemochromatosis; PAS-staining reveals AAT globules in AAT deficiency
  - HFE mutations in hemochromatosis versus SERPINA1 mutations in AAT deficiency
  evidence:
  - reference: PMID:20301692
    supports: SUPPORT
    snippet: "Liver disease in adults (manifesting as cirrhosis and fibrosis) may occur in the absence of a history of neonatal or childhood liver disease."
    explanation: "Adult-onset liver cirrhosis in AAT deficiency must be differentiated from other genetic causes"

notes: >
  Alpha-1 antitrypsin deficiency is a rare hereditary condition with significant clinical variability that requires early diagnosis and long-term management.
  Smoking cessation is the single most important intervention as tobacco smoke dramatically accelerates emphysema progression in AAT-deficient individuals.
  The ZZ genotype (homozygous for the Z allele) carries the highest disease risk. Protective threshold AAT levels are typically defined as 57 μM (11 μg/mL);
  individuals below this threshold should be considered for augmentation therapy. Risk of liver disease is further increased by excessive alcohol consumption and obesity,
  so lifestyle modifications are essential. AAT deficiency is associated with increased risk of hepatocellular carcinoma and lung cancer; regular surveillance is recommended.
  Heterozygous individuals may still have increased disease risk, particularly with environmental exposures. AAT deficiency can coexist with other genetic conditions
  (such as cystic fibrosis), resulting in more severe disease requiring intensive management. Recent therapeutic advances under investigation include gene therapy,
  induced pluripotent stem cell therapy, and novel approaches targeting AAT polymerization within hepatocytes. Liver transplantation is curative and expanding donor
  pools (including heterozygous donors) improves access to this definitive treatment. Early detection through newborn screening or targeted testing in symptomatic
  individuals is crucial for improving patient outcomes and quality of life.
datasets: